Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Sweanor

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
American Journal of Public Health|May 7, 2020
Placing the Legal Vape Market in the Hands of Big TobaccoAdam R Houston, Amelia Howard, David Sweanor
Preventive Medicine|July 1, 2020
The past is not the future in tobacco controlK Michael Cummings, Scott Ballin, David Sweanor
Tobacco Control|September 30, 2010
The case for OFSMOKE: how tobacco price regulation is needed to promote the health of markets, government revenue and the publicAnna B Gilmore, J Robert Branston, David Sweanor
The New England Journal of Medicine|August 13, 2015
Differential Taxes for Differential Risks--Toward Reduced Harm from Nicotine-Yielding ProductsFrank J Chaloupka, David Sweanor, Kenneth E Warner
The International Journal on Drug Policy|April 11, 2015
What to consider when regulating electronic cigarettes: Pros, cons and unintended consequencesPasquale Caponnetto, Daniela Saitta, David Sweanor, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Should e-cigarettes be regulated as a medicinal device?Peter Hajek, Jonathan Foulds, Jacques Le Houezec, et al.
Public Health Research (Southampton, England)|October 5, 2023
Effects of reduced-risk nicotine-delivery products on smoking prevalence and cigarette sales: an observational studyFrancesca Pesola, Anna Phillips-Waller, Emma Beard, et al.
Tobacco Control|September 6, 2019
Altria-Juul Labs deal: why did it occur and what does it mean for the US nicotine delivery product marketDavid T Levy, David Sweanor, Luz Maria Sanchez-Romero, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|January 24, 2023
Do Tobacco Companies Have an Incentive to Promote "Harm Reduction" Products?: The Role of CompetitionDavid T Levy, Frances Thirlway, David Sweanor, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of expertsDavid T Levy, Elizabeth A Mumford, K Michael Cummings, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
American Journal of Public Health|May 7, 2020
Placing the Legal Vape Market in the Hands of Big TobaccoAdam R Houston, Amelia Howard, David Sweanor
Preventive Medicine|July 1, 2020
The past is not the future in tobacco controlK Michael Cummings, Scott Ballin, David Sweanor
Tobacco Control|September 30, 2010
The case for OFSMOKE: how tobacco price regulation is needed to promote the health of markets, government revenue and the publicAnna B Gilmore, J Robert Branston, David Sweanor
The New England Journal of Medicine|August 13, 2015
Differential Taxes for Differential Risks--Toward Reduced Harm from Nicotine-Yielding ProductsFrank J Chaloupka, David Sweanor, Kenneth E Warner
The International Journal on Drug Policy|April 11, 2015
What to consider when regulating electronic cigarettes: Pros, cons and unintended consequencesPasquale Caponnetto, Daniela Saitta, David Sweanor, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Should e-cigarettes be regulated as a medicinal device?Peter Hajek, Jonathan Foulds, Jacques Le Houezec, et al.
Public Health Research (Southampton, England)|October 5, 2023
Effects of reduced-risk nicotine-delivery products on smoking prevalence and cigarette sales: an observational studyFrancesca Pesola, Anna Phillips-Waller, Emma Beard, et al.
Tobacco Control|September 6, 2019
Altria-Juul Labs deal: why did it occur and what does it mean for the US nicotine delivery product marketDavid T Levy, David Sweanor, Luz Maria Sanchez-Romero, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|January 24, 2023
Do Tobacco Companies Have an Incentive to Promote "Harm Reduction" Products?: The Role of CompetitionDavid T Levy, Frances Thirlway, David Sweanor, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 16, 2004
The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of expertsDavid T Levy, Elizabeth A Mumford, K Michael Cummings, et al.
Pageof 3